These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32211216)

  • 41. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.
    Thorne RG; Pronk GJ; Padmanabhan V; Frey WH
    Neuroscience; 2004; 127(2):481-96. PubMed ID: 15262337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space.
    Shrewsbury SB
    Pharmaceut Med; 2023 Nov; 37(6):451-461. PubMed ID: 37537422
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation.
    Shah P; Sarolia J; Vyas B; Wagh P; Ankur K; Kumar MA
    Curr Drug Deliv; 2021; 18(6):805-824. PubMed ID: 32640955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys.
    Sasaki K; Fukakusa S; Torikai Y; Suzuki C; Sonohata I; Kawahata T; Magata Y; Kawai K; Haruta S
    J Control Release; 2023 Jul; 359():384-399. PubMed ID: 37315691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipid Nanoparticles for Nasal/Intranasal Drug Delivery.
    Cunha S; Amaral MH; Lobo JMS; Silva AC
    Crit Rev Ther Drug Carrier Syst; 2017; 34(3):257-282. PubMed ID: 28845761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
    Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
    Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration.
    Lochhead JJ; Davis TP
    Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31726721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Translational Multimodality Neuroimaging.
    Sharma S
    Curr Drug Targets; 2017; 18(9):1039-1050. PubMed ID: 28302035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.
    Dhuria SV; Hanson LR; Frey WH
    J Pharm Sci; 2009 Jul; 98(7):2501-15. PubMed ID: 19025760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nano-in-Micro-Particles Consisting of PLGA Nanoparticles Embedded in Chitosan Microparticles via Spray-Drying Enhances Their Uptake in the Olfactory Mucosa.
    Spindler LM; Feuerhake A; Ladel S; Günday C; Flamm J; Günday-Türeli N; Türeli E; Tovar GEM; Schindowski K; Gruber-Traub C
    Front Pharmacol; 2021; 12():732954. PubMed ID: 34539414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting.
    Marcello E; Chiono V
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasal therapeutic strategies for management of Alzheimer's disease.
    Sood S; Jain K; Gowthamarajan K
    J Drug Target; 2014 May; 22(4):279-94. PubMed ID: 24404923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal drug delivery: opportunities and toxicologic challenges during drug development.
    Keller LA; Merkel O; Popp A
    Drug Deliv Transl Res; 2022 Apr; 12(4):735-757. PubMed ID: 33491126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physicochemical and physiological considerations for efficient nose-to-brain targeting.
    Bahadur S; Pathak K
    Expert Opin Drug Deliv; 2012 Jan; 9(1):19-31. PubMed ID: 22171740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal administration of CNS therapeutics to awake mice.
    Hanson LR; Fine JM; Svitak AL; Faltesek KA
    J Vis Exp; 2013 Apr; (74):. PubMed ID: 23608783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intranasal delivery of neuropeptides.
    Veronesi MC; Kubek DJ; Kubek MJ
    Methods Mol Biol; 2011; 789():303-12. PubMed ID: 21922417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2.
    Akita T; Kimura R; Akaguma S; Nagai M; Nakao Y; Tsugane M; Suzuki H; Oka JI; Yamashita C
    J Control Release; 2021 Jul; 335():575-583. PubMed ID: 34116136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A coupled bimodal SPECT-CT imaging and brain kinetics studies of zolmitriptan-encapsulated nanostructured polymeric carriers.
    Mandlik SK; Ranpise NS; Mohanty BS; Chaudhari PR
    Drug Deliv Transl Res; 2018 Jun; 8(3):797-805. PubMed ID: 29380155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Traditional neurotherapeutics approach intended for direct nose to brain delivery.
    Abolhasanzadeh Z; Ashrafi H; Badr P; Azadi A
    J Ethnopharmacol; 2017 Sep; 209():116-123. PubMed ID: 28733193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intranasal drug delivery for brain targeting.
    Vyas TK; Shahiwala A; Marathe S; Misra A
    Curr Drug Deliv; 2005 Apr; 2(2):165-75. PubMed ID: 16305417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.